[Pubmed] Complement and myasthenia gravis

[RSS-Bot]

Mol Immunol. 2022 Sep 2;151:11-18. doi: 10.1016/j.molimm.2022.08.018. Online ahead of print.

ABSTRACT

Myasthenia gravis is a neuromuscular disease associated with antibodies against components of the neuromuscular junction, most often against the acetylcholine receptor (AChR). Although several mechanisms have been postulated to explain how these autoantibodies can lead to the pathology of the disease, convincing evidence suggests that destruction of the receptor-bearing postsynaptic membrane by complement membrane attack complex is of central importance. In this review, evidence for the importance of complement, and possible relationships between autoantigen, autoantibodies, complement activation, and the destruction of the membrane are discussed. More recent insights from the results of the complement-inhibiting therapeutic antibody eculizumab are also described, and the mechanisms connecting antibody binding to complement activation are considered from a structural viewpoint.

PMID:36063582 | DOI:10.1016/j.molimm.2022.08.018


Source: https://pubmed.ncbi.nlm.nih.gov/3606358 ... 2&v=2.17.8